The Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) is actively seeking people with amyotrophic lateral sclerosis (ALS) to participate in a phase 2 clinical trial designed to evaluate whether Nuedexta has any effects on bulbar functions including speech, swallowing and saliva function.
Results from three recent studies — two supported in part by MDA — shed light on how the chromosome 9 open reading frame 72 (C9ORF72) mutation causes nerve cell death in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Trial investigators are actively seeking people with amyotrophic lateral sclerosis (ALS) to participate in a phase 2 clinical trial that will evaluate the effects of a five-drug treatment regimen used to suppress immune system activity.
The U.S. Department of Veterans Affairs (VA) is seeking veterans who have amyotrophic lateral sclerosis (ALS) and who live in the United States to enroll in its VA Biorepository Brain Bank (VABBB), a human tissue bank that collects, processes and stores tissue samples for use in future research studies.
A failure to repair damaged DNA appears to play an important role in amyotrophic lateral sclerosis (ALS), an MDA-supported team of researchers reports.
This roundup of recent amyotrophic lateral sclerosis (ALS) research and clinical trials news includes:
Muscular Dystrophy Association — USA
National Office222 S. Riverside Plaza, Suite 1500
Chicago, Illinois 60606(800) 572-1717
The Muscular Dystrophy Association (MDA) is a qualified 501(c)(3) tax-exempt organization.
©2015, Muscular Dystrophy Association Inc. All rights reserved.